Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of ONO-4578 combinations in metastatic non-small cell lung cancer after prior anti-PD-(L)1 therapy and platinum chemotherapy
jRCT2031200346Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ONO-4578, nivolumab, docetaxel and ramucirumab in non-small cell lung cancer (NSCLC), sponsored by Ono Pharmaceutical. Primary endpoints: Safety and Tolerability. Started Jun 2021; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031200346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200346.